-
2025-521764-35-00
5
acute pharyngitis
-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-523672-23-00
4
Metastatic Castrate Sensitive Prostate Cancer - mCSPC
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522484-15-00
5
2026-04-27
ER+/HER2- early breast cancer
-
2025-523100-77-00
4
2026-04-23
Ulcerative Colitis
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2025-524580-21-00
10
2026-06-01
Grass pollen induced allergic rhinitis or rhinoconjunctivitis
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2025-522642-44-00
4
2026-03-18
CHRONIC SPONTANEOUS URTICARIA
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-522482-30-00
4
2026-02-11
Actinic keratosis
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)